Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint

Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint

PR Newswire

CHENGDU, China, July 14, 2026

As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing conventional pemetrexed/platinum chemotherapy with sac-TMT, with significantly prolonged PFS and a positive OS trend compared with pembrolizumab plus pemetrexed and platinum-based chemotherapy.Focusing on the particularly challenging first-line treatment for PD-L1-negative non-squamous NSCLC population, the introduction of a TROP2 ADC to a PD-1 mAb not only delivers ADC's precise targeting and killing of tumor cells, but also activates the immune microenvironment through their synergetic mechanisms. This strategy is expected to unlock the therapeutic potential of the PD-1 mAb in patients with PD-L1-negative or limited immune responses, breaking this therapeutic bottleneck.Following the meeting of the primary endpoint in the Phase III OptiTROP-Lung05 study for first-line PD-L1-positive NSCLC, the positive results were achieved in another Phase III trial of sac-TMT plus pembrolizumab, providing robust clinical evidence supporting the expansion of this combination regimen to a broader first-line NSCLC population.CHENGDU, China, July 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Lung06) of its trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®), in combination with MSD's[1] anti-programmed cell death protein 1 (PD-1) therapy KEYTRUDA®[2] (pembrolizumab) as a first-line treatment for programmed death-ligand 1 (PD-L1)-negative locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) has met its primary endpoint of progression‑free survival (PFS) at a prespecified interim analysis. This is the world's first Phase III clinical study of an ADC combined with an immune checkpoint inhibitor to meet its primary endpoint in the first-line treatment of driver gene‑negative and PD‑L1‑negative non-squamous NSCLC.